Pravin Dugel Sells 21,156 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock

Posted by Brenda Bartman on May 28th, 2026

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) insider Pravin Dugel sold 21,156 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total value of $173,479.20. Following the completion of the sale, the insider directly owned 2,597,170 shares in the company, valued at $21,296,794. This trade represents a 0.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ocular Therapeutix Price Performance

Ocular Therapeutix stock traded up $0.61 during trading hours on Thursday, hitting $9.15. The stock had a trading volume of 3,382,545 shares, compared to its average volume of 5,029,148. The company has a debt-to-equity ratio of 0.12, a current ratio of 14.81 and a quick ratio of 14.73. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -6.27 and a beta of 0.93. Ocular Therapeutix, Inc. has a 1-year low of $6.23 and a 1-year high of $16.44. The stock’s fifty day moving average is $8.78 and its two-hundred day moving average is $10.24.

Institutional Trading of Ocular Therapeutix

Several institutional investors and hedge funds have recently made changes to their positions in OCUL. Millennium Management LLC lifted its position in shares of Ocular Therapeutix by 3,136.1% in the third quarter. Millennium Management LLC now owns 3,855,706 shares of the biopharmaceutical company’s stock valued at $45,073,000 after acquiring an additional 3,736,560 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Ocular Therapeutix by 2,003.2% in the third quarter. Alliancebernstein L.P. now owns 3,424,439 shares of the biopharmaceutical company’s stock valued at $40,032,000 after acquiring an additional 3,261,619 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Ocular Therapeutix by 38.5% in the third quarter. Avoro Capital Advisors LLC now owns 10,250,000 shares of the biopharmaceutical company’s stock valued at $119,822,000 after acquiring an additional 2,850,000 shares in the last quarter. Commodore Capital LP purchased a new position in Ocular Therapeutix during the first quarter worth about $21,810,000. Finally, Vanguard Group Inc. lifted its position in Ocular Therapeutix by 26.3% during the fourth quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock worth $140,523,000 after buying an additional 2,411,953 shares during the period. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

OCUL has been the topic of several research reports. Needham & Company LLC reissued a “buy” rating and issued a $18.00 target price on shares of Ocular Therapeutix in a report on Tuesday, May 5th. William Blair reissued an “outperform” rating on shares of Ocular Therapeutix in a report on Monday, March 2nd. Chardan Capital reissued a “buy” rating and issued a $21.00 target price on shares of Ocular Therapeutix in a report on Wednesday, February 18th. Royal Bank Of Canada reissued an “outperform” rating and issued a $30.00 target price on shares of Ocular Therapeutix in a report on Wednesday, May 6th. Finally, Citigroup restated an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $23.78.

Read Our Latest Report on OCUL

About Ocular Therapeutix

(Get Free Report)

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.